Catalent and MigVax today announced that they have signed a development agreement to leverage Catalent’s proprietary Zydis® Bio orally disintegrating tablet (ODT) technology for delivering the MigVax-101 vaccine against COVID-19.
Read more here.
Catalent and MigVax today announced that they have signed a development agreement to leverage Catalent’s proprietary Zydis® Bio orally disintegrating tablet (ODT) technology for delivering the MigVax-101 vaccine against COVID-19.
Read more here.
![[Ubimo in Yahoo Finance] Ubimo Location Intelligence Allows Kinetic to Connect the Digital and Physical Worlds for Out-of-Home (OOH) Advertisers](https://blog.ourcrowd.com/wp-content/themes/Extra/images/post-format-thumb-text.svg)
